IκBζ: an emerging player in cancer
Metrics: PDF 734 views | HTML 1272 views | ?
Marie Willems1, Nadège Dubois1, Lucia Musumeci1, Vincent Bours1 and Pierre A. Robe1,2
1 Department of Human Genetics and GIGA Research Center, University of Liège, Liege, Belgium
2 Department of Neurology and Neurosurgery, T&P Bohnenn Laboratory for Neuro-Oncology, Brain Center Rudolf Magnus, University Medical Center of Utrecht, Heidelberglaan, Utrecht, The Netherlands
Pierre A. Robe, email:
Keywords: IκBζ, nuclear IκB protein, NF-κB pathway, cancer, perspectives
Received: January 19, 2016 Accepted: August 23, 2016 Published: August 26, 2016
IκBζ, an atypical member of the nuclear IκB family of proteins, is expressed at low levels in most resting cells, but is induced upon stimulation of Toll-like/IL-1 receptors through an IRAK1/IRAK4/NFκB-dependent pathway. Like its homolog Bcl3, IκBζ can regulate the transcription of a set of inflamatory genes through its association with the p50 or p52 subunits of NF-κB. Long studied as a key component of the immune response, IκBζ emerges as an important regulator of inflammation, cell proliferation and survival. As a result, growing evidence support the role of this transcription factor in the pathogenesis number of human hematological and solid malignancies.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.